This HTML5 document contains 158 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/drugbank/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/iuphar/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/guide-to-pharmacology/
n6http://www.drugs.com/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/national-drug-code-directory/
n29http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/chemspider/
n12http://www.rxlist.com/cgi/generic/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/kegg-compound/
n16http://linked.opendata.cz/ontology/sukl/drug/
n17http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00540/identifier/pubchem-compound/

Statements

Subject Item
n2:DB00540
rdf:type
n3:Drug
n3:description
Nortriptyline hydrochloride, the <i>N</i>-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).
n3:dosage
n24:271B4242-363D-11E5-9242-09173F13E4C5 n24:271B4243-363D-11E5-9242-09173F13E4C5 n24:271B4244-363D-11E5-9242-09173F13E4C5 n24:271B4245-363D-11E5-9242-09173F13E4C5 n24:271B4241-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998 Oct 12;158(18):2035-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9778204
n3:group
approved
n3:halfLife
16 to 90+ hours
n3:indication
For the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
n3:manufacturer
n4:271B4222-363D-11E5-9242-09173F13E4C5 n4:271B4223-363D-11E5-9242-09173F13E4C5 n4:271B4220-363D-11E5-9242-09173F13E4C5 n4:271B4221-363D-11E5-9242-09173F13E4C5 n4:271B421F-363D-11E5-9242-09173F13E4C5 n4:271B4228-363D-11E5-9242-09173F13E4C5 n4:271B4226-363D-11E5-9242-09173F13E4C5 n4:271B4227-363D-11E5-9242-09173F13E4C5 n4:271B4224-363D-11E5-9242-09173F13E4C5 n4:271B4225-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00540 n29:DB00540
dcterms:title
Nortriptyline
adms:identifier
n8:4543 n9:46507783 n10:Nortriptyline n13:PA450657 n19:C07274 n20:54868-2835-2 n21:2404 n22:2404 n23:DB00540 n25:7640 n26:4384
n3:mechanismOfAction
It is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.
n3:packager
n4:271B420E-363D-11E5-9242-09173F13E4C5 n4:271B4213-363D-11E5-9242-09173F13E4C5 n4:271B41F4-363D-11E5-9242-09173F13E4C5 n4:271B4216-363D-11E5-9242-09173F13E4C5 n4:271B4217-363D-11E5-9242-09173F13E4C5 n4:271B41F7-363D-11E5-9242-09173F13E4C5 n4:271B4214-363D-11E5-9242-09173F13E4C5 n4:271B41F8-363D-11E5-9242-09173F13E4C5 n4:271B4215-363D-11E5-9242-09173F13E4C5 n4:271B41F5-363D-11E5-9242-09173F13E4C5 n4:271B41F6-363D-11E5-9242-09173F13E4C5 n4:271B41FB-363D-11E5-9242-09173F13E4C5 n4:271B41FC-363D-11E5-9242-09173F13E4C5 n4:271B41F9-363D-11E5-9242-09173F13E4C5 n4:271B41FA-363D-11E5-9242-09173F13E4C5 n4:271B41FF-363D-11E5-9242-09173F13E4C5 n4:271B4200-363D-11E5-9242-09173F13E4C5 n4:271B41FD-363D-11E5-9242-09173F13E4C5 n4:271B41FE-363D-11E5-9242-09173F13E4C5 n4:271B4210-363D-11E5-9242-09173F13E4C5 n4:271B4211-363D-11E5-9242-09173F13E4C5 n4:271B420F-363D-11E5-9242-09173F13E4C5 n4:271B421A-363D-11E5-9242-09173F13E4C5 n4:271B421B-363D-11E5-9242-09173F13E4C5 n4:271B4212-363D-11E5-9242-09173F13E4C5 n4:271B4219-363D-11E5-9242-09173F13E4C5 n4:271B421E-363D-11E5-9242-09173F13E4C5 n4:271B421C-363D-11E5-9242-09173F13E4C5 n4:271B421D-363D-11E5-9242-09173F13E4C5 n4:271B4218-363D-11E5-9242-09173F13E4C5 n4:271B4203-363D-11E5-9242-09173F13E4C5 n4:271B4204-363D-11E5-9242-09173F13E4C5 n4:271B4201-363D-11E5-9242-09173F13E4C5 n4:271B4202-363D-11E5-9242-09173F13E4C5 n4:271B4207-363D-11E5-9242-09173F13E4C5 n4:271B4208-363D-11E5-9242-09173F13E4C5 n4:271B4205-363D-11E5-9242-09173F13E4C5 n4:271B4206-363D-11E5-9242-09173F13E4C5 n4:271B420B-363D-11E5-9242-09173F13E4C5 n4:271B420C-363D-11E5-9242-09173F13E4C5 n4:271B4209-363D-11E5-9242-09173F13E4C5 n4:271B420A-363D-11E5-9242-09173F13E4C5 n4:271B420D-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately one-third of a single orally administered dose is excreted in urine within 24 hours. Small amounts are excreted in feces via biliary elimination.
n3:synonym
10,11-dihydro-N-Methyl-5H-dibenzo[a,D]cycloheptene-delta(5,gamma)-propylamine Desmethylamitriptyline Nortriptyline 3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine Aventyl Psychostyl Sensaval Demethylamitriptyline Ateben Noritren Avantyl
n3:toxicity
Symptoms of overdose include cardiac dysrhythmias, severe hypotension, shock, congestive heart failure, pulmonary edema, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
n16:hasAHFSCode
n18:28-16-04-28
n3:foodInteraction
Take with food to reduce irritation. Avoid alcohol. Avoid excessive quantities of coffee or tea (caffeine).
n3:proteinBinding
Highly protein-bound in plasma and tissues.
n3:salt
n3:synthesisReference
Abraham Nudelman, "ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME." U.S. Patent US20130184347, issued July 18, 2013.
foaf:page
n6:nortriptyline.html n12:nortrip.htm
n3:IUPAC-Name
n11:271B424A-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B4250-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B424F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B424C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B424D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B424E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B4248-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B4260-363D-11E5-9242-09173F13E4C5 n11:271B4246-363D-11E5-9242-09173F13E4C5 n11:271B4249-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B4247-363D-11E5-9242-09173F13E4C5
n3:pKa
n11:271B4261-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:N06AA10
n3:H-Bond-Acceptor-Count
n11:271B4256-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B4257-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B4251-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B4252-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B4254-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B4253-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B4255-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the GI tract. Peak plasma concentrations occur 7-8.5 hours following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
72-69-5
n3:category
n3:containedIn
n14:271B4229-363D-11E5-9242-09173F13E4C5 n14:271B422C-363D-11E5-9242-09173F13E4C5 n14:271B422D-363D-11E5-9242-09173F13E4C5 n14:271B422A-363D-11E5-9242-09173F13E4C5 n14:271B422B-363D-11E5-9242-09173F13E4C5 n14:271B4240-363D-11E5-9242-09173F13E4C5 n14:271B423E-363D-11E5-9242-09173F13E4C5 n14:271B423F-363D-11E5-9242-09173F13E4C5 n14:271B4230-363D-11E5-9242-09173F13E4C5 n14:271B4231-363D-11E5-9242-09173F13E4C5 n14:271B422E-363D-11E5-9242-09173F13E4C5 n14:271B422F-363D-11E5-9242-09173F13E4C5 n14:271B4234-363D-11E5-9242-09173F13E4C5 n14:271B4235-363D-11E5-9242-09173F13E4C5 n14:271B4232-363D-11E5-9242-09173F13E4C5 n14:271B4233-363D-11E5-9242-09173F13E4C5 n14:271B4238-363D-11E5-9242-09173F13E4C5 n14:271B4239-363D-11E5-9242-09173F13E4C5 n14:271B4236-363D-11E5-9242-09173F13E4C5 n14:271B4237-363D-11E5-9242-09173F13E4C5 n14:271B423C-363D-11E5-9242-09173F13E4C5 n14:271B423D-363D-11E5-9242-09173F13E4C5 n14:271B423A-363D-11E5-9242-09173F13E4C5 n14:271B423B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B425B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B425D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B425E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B425F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B425A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B4259-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B425C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B424B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B4258-363D-11E5-9242-09173F13E4C5